Screener
Vertex Pharmaceuticals VRTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
FAQ
- What is Vertex Pharmaceuticals's retained earnings?
- Vertex Pharmaceuticals (VRTX) reported retained earnings of $14.59B in Q1 2026.
- How has Vertex Pharmaceuticals's retained earnings changed year-over-year?
- Vertex Pharmaceuticals's retained earnings increased by 42.3% year-over-year, from $10.25B to $14.59B.
- What is the long-term trend for Vertex Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's retained earnings has grown at a 73.7% compound annual growth rate (CAGR), from $858.7M to $13.56B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Vertex Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude